16 September 2016

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, is proud to announce that it has retained its position as an index component on the Dow Jones Sustainability Indices (DJSI).

Since 1999, the DJSI tracks the financial performance of the leading sustainability-driven companies worldwide based on an analysis of financially relevant economic, environmental, and social factors. Smith & Nephew is included in both the 2016 DJSI World and DJSI Europe Indices. Smith & Nephew has now been a member of DJSI World since 2002 and a member of DJSI Europe since 2001.

In the Healthcare Equipment and Supplies sector, Smith & Nephew is one of only seven members of the DJSI World Index and one of just three members for DJSI Europe. Smith & Nephew scored highly in Climate Strategy, Occupational Health and Safety, Social Reporting and was awarded a perfect score in the Environmental Reporting category, illustrating the company’s continued excellence in sustainable operations.

Olivier Bohuon, Chief Executive Officer of Smith & Nephew, said:

“We are firmly committed to making a meaningful contribution across all three pillars of sustainability – social, environmental and economic. Our emphasis is on delivering positive outcomes that advance the long-term prospects for our business everywhere we operate. We will continue to strive to be a responsible business that sets an example for others. ”

Media

Charles Reynolds, Corporate Communications
Smith & Nephew
+44 (0)20 7401 7646

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management,Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2015 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

_{Forward-looking Statements}

_{This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.}  

WALTHAM, Mass., Sept. 16, 2016 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that it has entered into a definitive securities purchase agreement to raise approximately $30.0 million in a private placement of common stock, Series A Convertible Preferred Stock and warrants exercisable for common stock.  The private placement is being led by new healthcare dedicated institutional investors, with participation by certain existing investors.

Histogenics expects to use the net proceeds from the private placement to support the development of NeoCart^®, its novel cartilage repair therapy, including the completion of the ongoing Phase 3 clinical trial, and for general corporate and working capital purposes.  Upon the closing of the private placement, Histogenics expects the proceeds raised in the offering along with its existing cash resources to last through the middle of 2018.  Based on Histogenics’ current plans, enrollment in the NeoCart Phase 3 clinical trial will be completed in the second quarter of 2017, with topline data on its 1-year primary efficacy endpoint available by the middle of 2018.

Pursuant to the terms of the securities purchase agreement, Histogenics has agreed to sell 2,653,553 shares of common stock at a price of $2.25 per share and 24,158.8688 shares of newly created Series A Convertible Preferred Stock, which shares of preferred stock are convertible into approximately 10,679,781 shares of common stock.  Purchasers will receive warrants to purchase up to approximately 13,333,334 shares of common stock at an exercise price of $2.25 per share.  The warrants will be exercisable following approval of the private placement byHistogenics stockholders and will expire 5 years from the date of such stockholder approval.  The closing of the offering is subject to the satisfaction of customary closing conditions.

Affiliates of certain members of Histogenics’ Board of Directors agreed to purchase an aggregate of 283,045 shares of common stock and 2,563.1451 shares of Series A Convertible Preferred Stock in the private placement and will receive warrants to purchase up to 1,422,221 shares of Histogenics’ common stock at an exercise price of $2.25 per share.

H.C. Wainwright & Co., LLC served as the sole placement agent in connection with this offering.

The securities to be sold in the private placement will not have been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United Statesabsent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements.  Histogenics has agreed to file one or more registration statements with the SECregistering the resale of the shares of common stock purchased in the private placement and the shares of common stock underlying the warrants and issuable upon conversion of the Series A Convertible Preferred Stock.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Histogenics Corporation

Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace.  Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions.  Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development.  NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells.  Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year.  NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options.  For more information, please visit www.histogenics.com.

Forward –Looking Statements

Various statements in this release are “forward-looking statements” under the securities laws.  Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,”  “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements.  Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.

Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others:  the expected closing and closing date of the offering and the use of proceeds of the offering and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Histogenics’ Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, which are on file with the SEC and available on the SEC’s website at www.sec.gov. In addition to the risks described above and in Histogenics’ annual report on Form 10-K and quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Histogenics’ results.

There can be no assurance that the actual results or developments anticipated by Histogenics will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Histogenics.  Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Histogenics or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.  Histogenicscautions investors not to rely too heavily on the forward-looking statements Histogenics makes or that are made on its behalf.  The information in this release is provided only as of the date of this release, and Histogenics undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Investor Relations

Tel: +1 (781) 547-7909

InvestorRelations@histogenics.com

Histogenics Corporation

By Tom Howell Jr. – The Washington Times – Thursday, September 15, 2016

California Democrats are testing the bounds of Obamacare’s “innovation” waiver, pushing to bypass the 2010 law’s ban on illegal immigrants’ participation by letting them purchase insurance on the state’s health care exchange.

Capitol Hill Democrats, who created the ban over fear that allowing illegals to enroll would be too politically charged, now sense a shift in their favor. They say it’s time to let those in the country without authorization buy into Obamacare as long as they cover all the costs themselves.

The California plan is poised to be the first major test for President Obama and his waiver authority. The White House is not tipping its hand, saying it will wait to see an official proposal.

Waivers were written into Section 1332 of the Affordable Care Act as a way to let states experiment on whether they could provide the same level of coverage without having to follow all of the law’s strict rules.

The waivers don’t take effect until next year because the law’s authors wanted to force states to play by the rules at first.

Vermont and Hawaii are the only states to submit waiver requests so far and have requested modest changes to how Obamacare’s small-business exchanges are implemented.

Other states see California as a test.

If California succeeds, “that may signal to some states, ‘Hey, there’s an openness here to thinking a little bit more broadly,’ and we may see then some states moving forward,” said Jennifer Tolbert, director of state health care reform at the nonpartisan Kaiser Family Foundation.

READ THE REST HERE

Dublin – September 15, 2016 – Medtronic (NYSE: MDT) today announced the appointment of Mark Ploof as Senior Vice President, Global Operations and Business Services effective October 31, 2016.  He will serve on the company’s Executive Committee and be responsible for leading Medtronic’s Global Operations, Information Technology, Facilities & Real Estate and Medtronic Business Services functions, which include the company’s ongoing Covidien acquisition integration efforts.

Ploof succeeds Gary Ellis who previously announced plans to retire from the company later this fiscal year after a 27-year Medtronic career. As part of a planned succession, Ellis will remain on the Medtronic Executive Committee and work with Ploof to ensure a smooth transition.

“Mark brings a diverse range of experiences to the Medtronic leadership team as well as a relentless focus on creating operational excellence, value creation and business growth,” said Omar Ishrak, Medtronic Chairman and CEO. “It is an exciting and transformational time for Medtronic, and I am confident in Mark’s ability to help us deliver against our strategic business priorities.  From his broad knowledge of operations to his expertise in assessing and identifying opportunities to operate at scale and generate margin expansion, Mark’s vast experiences in a multitude of industries will bring fresh thinking and leadership to our organization.”

“I’m excited for this opportunity with Medtronic and to play such a vital role in helping the company achieve its Mission around the world,” said Ploof. “I am particularly pleased to join the men and women of Medtronic in these functional areas who are driving world class business performance and efficiencies in their work, and I know that we will play an instrumental part in helping Medtronic realize its operational and financial goals in the coming years.”

Ploof worked with Cerberus Capital Management portfolio companies to drive margin expansion, efficiency and value creation efforts in a variety of operations, industries and roles. He brings a track record of assessing, diagnosing and remediating opportunities to capture value and institute new operational and service delivery models to operate efficiently at scale. His business development background at GE and Cerberus companies included creating and executing company integration plans and programs, including facility and supply chain consolidations, shared services and centers of excellence creation and organizational development and alignment efforts.

Ploof joins Medtronic from YP, LLC where he most recently served as the Chief Customer Experience Officer. As a member of YP’s Operating Leadership Team, Ploof oversaw centralized and field service management, quality and operational enablement, and business intelligence. He also served as the company’s Chief Restructuring Officer, focused on YP’s spin-off from AT&T. Under his leadership, YP established and drove significant shareholder returns and significantly improved customer engagement and satisfaction scores.

Ploof has also held senior leadership roles in finance, supply chain, business development and sourcing in Cerberus portfolio companies and at General Electric, where he established a track record of establishing large scale operating models that generated meaningful efficiencies and value creation.  Ploof holds a bachelor of business administration degree in Management from Pace University.

About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Contacts:
Fernando Vivanco
Public Relations
+1-763-505-3780

Ryan Weispfenning
Investor Relations
+1-763-505-4626

FARMINGDALE, N.Y., Sept. 14, 2016 /PRNewswire/ — Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, neurosurgery, wound debridement, skull based surgery, laparoscopic surgery and other surgical applications, announced that it filed a Form 12b-25 (the “Filing”) today with the Securities and Exchange Commission indicating that Misonix likely will not be in a position to file its Annual Report on Form 10-K for the fiscal year ended June 30, 2016 within the 15-day extension period provided in Rule 12b-25(b) under the Securities Exchange Act of 1934.

The Filing stated that the Audit Committee of the Company has determined that deficiencies existed in the Company’s internal control over financial reporting at June 30, 2016. The Audit Committee is still considering whether or not the deficiencies constitute one or more material weaknesses in the Company’s internal control over financial reporting at such date. Notwithstanding its determination, the Audit Committee has no current information to suggest that the Company’s previously reported financial statements and results are incorrect in any material respect. The filing of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 will be delayed pending completion of an investigation relating to these deficiencies being overseen by the Audit Committee. The filing may also be delayed as a result of the appointment effectiveSeptember 13, 2016 by the Board of Directors of the Company of Joseph Dwyer as interim Chief Financial Officer. Richard A. Zaremba, Senior Vice President and Chief Financial Officer through September 13, 2016, has been appointed Senior Vice President, Finance. The Company is working diligently to resolve these matters and intends to file its Annual Report on Form 10-K as promptly as reasonably practicable.

Preliminary results for the fiscal year ended June 30, 2016 are net sales of $23.1 million and a net loss ranging from $(1.0) million to $(1.3) million for the fiscal year ended June 30, 2016 as compared to net sales of $22.2 million and net income of $5.6 million for the fiscal year ended June 30, 2015, which included a $2.9 million reversal of the valuation allowance previously recorded against deferred tax assets. On a per share basis, such preliminary results represent a net loss per share – basic ranging from $(0.13) to $(0.17) and a net loss per share – diluted ranging from $(0.13) to $(0.17) for the fiscal year ended June 30, 2016 as compared to net income per share – basic of $0.74 and net income per share – diluted of $0.69. The preliminary net loss for the fiscal year ended June 30, 2016 is attributable to higher operating expenses, including higher sales and marketing expense.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix’s proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, the completion of the investigation related to identified deficiencies in internal control over financial reporting, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Logo – http://photos.prnewswire.com/prnh/20160201/328020LOGO

SOURCE Misonix, Inc.

Related Links

http://www.misonix.com

WARSAW, Ind., Sept. 15, 2016 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, recently announced the strategic acquisition of Clinical Graphics, B.V., a novel imaging company specializing in 3D range-of-motion simulation technology to inform treatment decisions for common hip conditions requiring early intervention. Zimmer Biomet plans to integrate the new imaging platform to enhance its hip preservation portfolio.

“3D imaging represents the next generation of treating joint pain, and we’re excited to team up with Clinical Graphics and integrate our technologies to further enhance the clinical utility of our market leading hip portfolio,” said Dan Williamson, Group President, Joint Reconstruction for Zimmer Biomet.

Clinical Graphics is a recognized pioneer in the field of 3D interactive range-of-motion simulation reports for common hip conditions such as femoroacetabular impingement and dysplasia, and physicians rely on its technology to characterize the physiology of a patient’s pain and direct treatment approaches.

“Zimmer Biomet is a well-respected leader in musculoskeletal healthcare, and an ideal parent company to usher our breakthrough technologies into mainstream clinical practice as the standard of care for managing joint disease,” said Peter Krekel, Managing Director of Clinical Graphics. “We’re thrilled to join the Zimmer Biomet family and look forward to working together to improve the care of patients living with joint pain.”

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

About Clinical Graphics
Clinical Graphics began in 2010 as a spin-off from Delft University of Technology and is headquartered in The Netherlands at technology incubator Yes! Delft. The company enables physicians to see beyond the usual by converting medical scans into 3D motion simulations of patients’ anatomy. Clinical Graphics’ analysis reports provide an interactive 360◦ dynamic view of the joint, supporting both physicians and patients to make well-informed treatment decisions. For more information, visitwww.clinicalgraphics.com.

Logo – http://photos.prnewswire.com/prnh/20150624/225371LOGO

SOURCE Zimmer Biomet Holdings, Inc.

Related Links

http://www.zimmerbiomet.com

READ THE REST HERE